Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...
Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
Zealand Pharma completes enrollment in ZUPREME-1 trial
Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...
The Manila Times16h
Transaction in Own Shares
No ordinary shares are held in treasury. Therefore, the total number of voting rights in the Company is 369,545,021.